Advertisement
AMGN vs PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Amgen has delivered stronger revenue growth and higher profit margins in recent quarters compared to Pfizer, supported by key product launches and pipeline progress.
- Pfizer maintains a higher dividend yield and has raised its full-year revenue guidance amid steady non-COVID product performance.
- Amgen shares experienced a sharp correction in recent weeks following spillover effects from a competitor's clinical trial setback in the Lp(a) space.
- Pfizer's oncology portfolio, bolstered by acquired assets, continues to show operational growth while the company emphasizes cost discipline.
- Both companies operate in the biopharmaceutical sector with exposure to innovation-driven growth and regulatory risks, though Amgen's focus leans more toward biotechnology specialties.
- Relative performance shows Amgen with higher year-to-date gains historically, offset by recent volatility, while Pfizer offers more defensive characteristics through dividends and scale.
Introduction
Amgen and Pfizer represent two established players in the biopharmaceutical industry, offering investors exposure to innovative drug development, established product portfolios, and evolving pipelines. This comparison examines their recent business performance, market positioning, and relative momentum to assist traders and long-term investors evaluating healthcare sector allocations. The analysis draws on verifiable financial metrics, earnings outcomes, and sector developments from the past several weeks to provide a balanced view suitable for those assessing growth-oriented biotechnology versus large-scale pharmaceutical strategies in the current environment.
AMGN Overview and Recent Performance
Amgen develops and commercializes therapies in oncology, cardiovascular disease, inflammation, and rare conditions. In recent market activity, AMGN shares declined approximately 15% over five consecutive trading days amid broader sector pressure following a competitor's Phase 3 trial miss in the Lp(a) cardiovascular area, which raised questions about Amgen's competing candidate. Despite the pullback, the company reported robust second-quarter results with revenue of $10.1 billion, up nearly 10% year over year, and raised full-year guidance. Positive late-stage data for its IMDELLTRA combination in small cell lung cancer provided additional support. Year-to-date performance remains positive, reflecting underlying business strength in growth drivers such as Repatha and TEPEZZA.
PFE Overview and Recent Performance
Pfizer focuses on vaccines, oncology, internal medicine, and rare diseases, with a large global commercial footprint. In recent periods, PFE delivered second-quarter revenue of $15.03 billion, exceeding expectations, and raised the midpoint of its 2026 revenue guidance to $61.5 billion. Non-COVID product sales grew operationally, driven by oncology assets including Padcev and contributions from launched and acquired medicines. The stock has shown resilience with modest month-to-month gains and a dividend yield exceeding 6%. Recent emphasis on cost savings exceeding $10 billion and pipeline readouts in oncology and other areas has helped stabilize sentiment following post-pandemic revenue normalization.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers across varied market conditions. Only those demonstrating the strongest alignment with prevailing trends, risk-adjusted performance, and suitability for current environments appear in the trending section. Available bots span multiple trading styles, strategies, timeframes, and performance statistics, with historical win rates and drawdown metrics varying widely depending on the specific model and ticker set. This diversity allows users to explore options matching their preferred approach. Review the full selection of Trending AI Robots for detailed performance data.
Head-to-Head Comparison
Amgen operates with a biotechnology emphasis on specialized therapies and higher operating margins, while Pfizer leverages scale across vaccines, oncology, and established brands with a more diversified revenue base. Growth drivers differ: Amgen benefits from rapid uptake in select franchises and pipeline catalysts such as lung cancer combinations, whereas Pfizer highlights expansion in launched oncology products and cost efficiencies. Recent momentum favors Amgen's fundamentals despite short-term volatility, contrasted with Pfizer's steadier trajectory and shareholder returns via dividends. Risk factors include clinical and regulatory outcomes for both, with Amgen more exposed to biotechnology-specific trial readouts and Pfizer to patent expirations and large-scale commercial execution. Sector exposure remains similar within healthcare, yet market sentiment has reflected Amgen's premium valuation alongside Pfizer's value characteristics.
Tickeron AI Verdict
Based on observable factors including trend consistency in core growth products, margin stability, and relative positioning after recent volatility, Tickeron’s AI models would currently assign a modest probabilistic edge to AMGN for investors seeking exposure to innovation-driven momentum, while noting Pfizer's stronger defensive profile through dividends and scale. This assessment remains subject to ongoing market conditions and new data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Hold and PFE is a Hold.
| AMGN | PFE | AMGN / PFE | |
| Capitalization | 208B | 158B | 132% |
| EBITDA | 17.6B | 13.5B | 130% |
| Gain YTD | 20.235 | 16.818 | 120% |
| P/E Ratio | 23.95 | 36.39 | 66% |
| Revenue | 38.1B | 63.7B | 60% |
| Total Cash | 14B | 11.7B | 120% |
| Total Debt | 57.3B | 63.2B | 91% |
AMGN | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 94 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 17 Undervalued | |
PROFIT vs RISK RATING 1..100 | 12 | 100 | |
SMR RATING 1..100 | 15 | 83 | |
PRICE GROWTH RATING 1..100 | 46 | 46 | |
P/E GROWTH RATING 1..100 | 32 | 5 | |
SEASONALITY SCORE 1..100 | 50 | 41 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (6) in the Biotechnology industry is in the same range as PFE (17) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
AMGN's Profit vs Risk Rating (12) in the Biotechnology industry is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (46) in the Biotechnology industry is in the same range as PFE (46) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew similarly to PFE’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as AMGN (32) in the Biotechnology industry. This means that PFE’s stock grew similarly to AMGN’s over the last 12 months.
| AMGN | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | 2 days ago 54% |
| Stochastic ODDS (%) | 2 days ago 57% | 2 days ago 49% |
| Momentum ODDS (%) | 2 days ago 42% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 40% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 47% | 2 days ago 50% |
| Advances ODDS (%) | 2 days ago 62% | 2 days ago 54% |
| Declines ODDS (%) | 9 days ago 47% | 4 days ago 56% |
| BollingerBands ODDS (%) | 2 days ago 58% | 2 days ago 53% |
| Aroon ODDS (%) | 2 days ago 54% | 2 days ago 51% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 4 FA rating(s) are green while PFE’s FA Score has 2 green FA rating(s).
- AMGN’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- AMGN’s TA Score: 5 bullish, 5 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.20% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.82%. For the same industry, the average monthly price growth was -6.21%, and the average quarterly price growth was +15.37%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.82% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.07% | ||
| BMY - PFE | 57% Loosely correlated | +0.35% | ||
| MRK - PFE | 55% Loosely correlated | -0.19% | ||
| AMGN - PFE | 53% Loosely correlated | +1.55% | ||
| BIIB - PFE | 51% Loosely correlated | -1.62% | ||
| GSK - PFE | 48% Loosely correlated | -1.65% | ||
More | ||||